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Lessons From NPC1L1, HMGCR, PCSK9, APOC3, and CETP*Sekar Kathiresan, MDSEE PAGE 1552C oronary heart disease (CHD) remains theleading cause of death in the industrializedworld and will soon become so worldwide
(1). Much research has focused on biological risk fac-
tors and developing medicines to modify them. How-
ever, remarkably few medicines (e.g., aspirin, statins,
and antihypertensive agents) are proven to reduce
CHD risk.
In several recent, large-scale, randomized-controlled
trials, newly-developed medicines (e.g., dalcetrapib
and darapladib) showed no beneﬁt over placebo in
reducing risk for coronary events (2–4). Often, these
late-stage failures come after decades of research
effort. Why were these results not anticipated? Two
reasons stand out (5). First, the ﬁeld has traditionally
depended on in vitro or animal models; however, pre-
clinical disease models often have limited ability to
predict beneﬁt in patients. For example, atheroscle-
rosis in humans is the result of genetic makeup and
decades of atherogenic stimuli; it is not surprising
that this is difﬁcult to recapitulate in cells or in
nonhuman model organisms. Second, drugs that
block a speciﬁc gene target are sometimes taken for
many years; we often do not know the effect over
such an extended period.*Editorials published in the Journal of the American College of Cardiology
reﬂect the views of the authors and do not necessarily represent the
views of JACC or the American College of Cardiology.
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medicine will reduce risk for clinical CHD without
adverse effects? In this issue of the Journal, Ference
et al. (6) show that the human genome may be a
valuable tool for prioritizing molecular targets in drug
development. Medicines are typically designed to
target a speciﬁc gene and its protein product. There is
naturally occurring variation in nearly every gene,
some of which resides in a speciﬁc drug’s target gene.
If this deoxyribonucleic acid (DNA) sequence varia-
tion modulates the gene’s function or expression,
then the phenotypic consequences of this variation
in the human population could anticipate if a drug
will safely reduce disease risk.This approach has now been applied to several
drug-gene pairs. Some of the drugs are already in
clinical use (ezetimibe targeting NPC1L1, statins tar-
geting HMGCR) and some are in development (drugs
targeting PCSK9, APOC3, and CETP). We will review
each of these examples to understand the strengths
and limitations of using genotype-phenotype corre-
lations to anticipate a medicine’s potential efﬁcacy
and safety.
Ezetimibe lowers plasma levels of low-density li-
poprotein cholesterol (LDL-C) by blocking the Nie-
mann–Pick C1-like 1 (NPC1L1) protein, a transporter
allowing dietary cholesterol to enter the body from
the intestinal lumen (7). Experiments in cells and mice
conﬁrmed that ezetimibe tightly binds to and blocks
NPC1L1, and targeted deletion of Npc1l1 in mice low-
ered plasma cholesterol and reduced atherosclerosis
(8,9). In human volunteers, ezetimibe treatment
blocked dietary cholesterol absorption by about 50%
(10). However, addition of ezetimibe to background
statin therapy failed to prevent atherosclerotic
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1563progression, as assessed by carotid intima-media
thickness (11). These results raised uncertainty as to
whether lowering LDL-C with ezetimibe would reduce
risk for clinical CHD.
Ference et al. (6) mined the human genome to
address this uncertainty. If ezetimibe successfully
reduces risk for clinical CHD, DNA sequence variants
that reduce NPC1L1 function (i.e., mimicking ezeti-
mibe action) would be expected to lower LDL-C
and protect against CHD risk. The results of several
recently-published, large, genome-wide searches
for DNA sequence variants affecting plasma LDL-C
(12,13) were leveraged by Ference et al. (6) to
pinpoint 5 independent variants at or near the
NPC1L1 gene and develop a genetic score using
these variants. Those with an NPC1L1 gene score
below the median had a 2.4 mg/dl lower LDL-C level
than those with scores above the median. After
testing the NPC1L1 gene score in 108,376 individuals,
the investigators found that those with the lower
gene scores also had reduced risk for CHD (4.8%
lower).
Late last year, we published ﬁndings (14) consistent
with those of Ference et al. (6). Through sequencing of
the protein-coding regions of NPC1L1, we found that
approximately 1 in 650 persons carried a large-effect
mutation (nonsense, splice-site, or frameshift; “null”
mutations) that completely inactivated 1 of the
2 copies of NPC1L1 present in each genome. Ezeti-
mibe mimics heterozygous null mutations, as both
reduce protein function by about one-half. We found
thatNPC1L1 nullmutation carriers had a 12mg/dl lower
LDL-C level (an effect size similar to ezetimibe treat-
ment) and 53% lower risk for CHD. Together, both
studies provide a strong therapeutic hypothesis that
ezetimibe, a small-molecular inhibitor of NPC1L1,
will not only lower LDL-C, but will also reduce risk
for CHD.
The IMPROVE-IT (ImprovedReduction ofOutcomes:
Vytorin Efﬁcacy International Trial; NCT00202878) has
validated this hypothesis. To establish the clinical
beneﬁt and safety of ezetimibe, 18,144 high-risk in-
dividuals presenting with an acute coronary syndrome
were randomized to simvastatin monotherapy versus
simvastatin/ezetimibe combined therapy (15). The
addition of ezetimibe signiﬁcantly reduced the pri-
mary endpoint (cardiovascular death, myocardial
infarction, unstable angina requiring hospitalization,
coronary revascularization, or stroke), with a relative
risk reduction of 6.4% and an absolute risk reduction
of 2% over 7 years of treatment. This was the ﬁrst
trial to demonstrate that adding a nonstatin agent
to a statin provides incremental clinical beneﬁt.
The average achieved LDL-C was 54 mg/dl withezetimibe/simvastatin dual therapy versus 70 mg/dl
with simvastatin monotherapy. These data suggest
that, in the setting of secondary prevention, we
should target LDL-C to levels even lower than con-
ventional thresholds.
Beyond ezetimibe-NPC1L1, there are now at least
4 other examples of drug-gene pairs affecting cardio-
vascular therapeutics, suggesting that this approach
may be generalizable (Table 1 summarizes all 5 exam-
ples). Statins and their therapeutic target gene,
3-hydroxy-3-methylglutaryl-CoA reductase (HMGCR),
are another notable example. Numerous individual
trials and comprehensive meta-analyses show that
statins reduce the risk for either a ﬁrst or recurrent
CHD event (16). Although available for more than 2
decades, we only recently appreciated that statins
lead to 2 important adverse events—modest weight
gain and a small increase in the relative risk for
type 2 diabetes (17,18). Could these adverse events
have been anticipated using modern human genetic
approaches?
We identiﬁed a naturally-occurring HMGCR gene
variation associated with lower LDL-C that led to
lower hepatic messenger ribonucleic acid expression
and, thereby, a loss of gene function (19). Swerdlow
et al. (18) demonstrated that those harboring an LDL-
lowering allele at either of 2 HMGCR polymorphisms
displayed higher body weight, increased fasting in-
sulin, higher plasma glucose, and increased risk for
type 2 diabetes. Clinical trial and genetic data are,
thus, remarkably concordant in identifying both the
efﬁcacy and toxicity of statin therapy. Importantly,
these data suggest that weight gain and glucose
intolerance induced by statins is related to HMGCR
inhibition, that is, an on-target class effect, rather
than the characteristics of a single agent or off-target
toxicity.
What might be the net effect on CHD of an inter-
vention that lowers LDL-C while simultaneously
increasing the risk of type 2 diabetes? From a meta-
analysis of statin trials in the secondary prevention
setting, it is clear that CHD risk is reduced with statin
treatment (20). Importantly, human genetics suggests
the same. In the study by Ference et al. (6), a genetic
score of HMGCR polymorphisms was associated not
only with lower LDL-C, but also with lower risk
of CHD.
There are 3 examples of variation in target genes
with therapies in development: PCSK9, APOC3, and
CETP. About 1 in 50 black people carry a null muta-
tion at the proprotein convertase subtilisin/kexin
type 9 (PCSK9) gene, causing lifelong inactivation
of 1 copy of the gene (21). These individuals have 28%
lower LDL-C and are protected from CHD (88% lower
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1564risk), suggesting that therapies directed against
PCSK9 should not only lower plasma LDL-C, but
should also reduce risk for CHD. Monoclonal anti-
bodies directed against PCSK9 reproducibly lower
plasma LDL-C in humans, and several randomized
trials are testing whether they reduce CHD in the
secondary prevention setting (22). About 1 in 150
whites and blacks carry a null mutation, at the
apolipoprotein C-III (APOC3) gene, leading to lifelong
inactivation of 1 copy of the gene (23,24). These in-
dividuals display a favorable plasma lipid phenotype
(lower triglycerides, lower LDL-C, lower remnant
cholesterol, and higher high-density lipoprotein
cholesterol [HDL-C]) and are protected from CHD
(40% lower risk). These genetic data bolster enthu-
siasm for triglyceride-rich lipoproteins as a modiﬁ-
able risk factor and suggest that therapies targeting
APOC3 should not only modify plasma lipids favor-
ably, but should also lower CHD risk. Antisense
oligonucleotide therapy targeting APOC3 was shown
to lower plasma triglyceride-rich lipoproteins in
humans, and it remains to be seen whether it will
lower CHD risk (25).
Finally, the cholesterol ester transfer protein
(CETP) has been studied intensively as a therapeutic
target. Several small molecules (anacetrapib, evace-
trapib) inhibit CETP, leading to increased plasma
HDL-C and decreased plasma concentrations of LDL-
C, triglycerides, and lipoprotein(a) (26,27). About 6
in 100 individuals of East Asian ancestry carry a
missense mutation at CETP (D442G), leading to loss of
protein function and elevated plasma HDL-C levels
(about 7 mg/dl higher) (28). It is still uncertain if CETP
D442G carriers are protected from CHD. However, a
recent study showed that they are at 70% increased
risk for age-related macular degeneration (AMD), a
leading cause of blindness in the United States (29). A
common noncoding variant at CETP (rs3764261, 32%
frequency) was previously shown to increase both
HDL-C and AMD risk (about 3.4 mg/dl increase in
HDL-C and 19% increase in AMD risk) (12,30). These
genetic data suggest the hypothesis that CETP inhi-
bition may lead to an on-target adverse event of AMD.
Randomized controlled trials of CETP inhibition
are ongoing with anacetrapib (REVEAL [Randomized
EValuation of the Effects of Anacetrapib Through
Lipid-modiﬁcation]; NCT01252953) and evacetrapib
(ACCELERATE [A Study of Evacetrapib in High-
Risk Vascular Disease]; NCT01687998). These trials
should clarify whether the genetic prediction of an
adverse event will hold true. Of note, the effect of
CETP D442G (or any germline genetic variant) on a
phenotype relates to lifelong modulation, whereas
the effect of a medicine typically reﬂects modulation
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1565starting in adulthood; as such, one may not augur
the other.
These ﬁve examples show the promise of using
human genetics to prioritize molecular targets. How
can we best expand the use of this approach? One
recent idea is a U.S. Precision Medicine Initiative
proposed by President Obama (31). Planning is un-
derway for the recruitment of a new national
research cohort linking genomic information to
clinical phenotypes. At least 3 key elements seem
important for optimally designing such a cohort for
making observations like those in Table 1. Many null
mutations that decrease disease risk and provide a
strong therapeutic hypothesis will be extremely rare
(often <1 in 1,000 frequency); thus, a large sample
size will be required to conﬁdently relate genotype
to phenotype. A research cohort of approximately 1
million Americans is envisioned. Mutations vary in
frequency by ethnicity and may be ethnic-speciﬁc
(e.g., PCSK9 null mutations in African Americans);
including a broad range of ethnic groups should
enhance the probability of success. Finally, discov-
ery of unanticipated biological connections, such
as between HDL-C and eye disease, requires a rich
set of clinical phenotypes for each participant.Electronic health records could provide this, and a
plan is being considered to link each volunteer’s
genomic information and electronic health record.
When combined with creative analytics of the
sort performed by Ference et al. (6), the Precision
Medicine Initiative could become a transformative
resource for understanding human biology and
catalyzing the development of novel therapeutics.
It is now possible to systematically identify DNA
sequence variations in therapeutic target genes, un-
derstand their phenotypic consequences, and use this
information to anticipate a medicine’s safety and ef-
ﬁcacy. We have an unprecedented opportunity to
leverage the genome’s natural successes by scouring
it for mutations that protect against disease with
minimal adverse effects and developing medicines
that mimic them.
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